Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Ultragenyx Pharmaceutical Inc. (RARE) had Receiveable Turnover of 4.60 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$560.23M |
|
$-569.18M |
|
$76.73M |
|
$483.50M |
|
$1.10B |
|
$-535.97M |
|
$-31.61M |
|
$-567.59M |
|
$-567.59M |
|
$-569.18M |
|
$-569.18M |
|
$-569.18M |
|
$-569.18M |
|
$-535.97M |
|
$-513.05M |
|
90.54M |
|
90.54M |
|
$-6.29 |
|
$-6.29 |
|
| Balance Sheet Financials | |
$817.12M |
|
$265.93M |
|
$686.33M |
|
$1.50B |
|
$344.15M |
|
-- |
|
$904.01M |
|
$1.25B |
|
$255.30M |
|
$32.58M |
|
$255.30M |
|
92.48M |
|
| Cash Flow Statement Financials | |
$-414.19M |
|
$-17.77M |
|
$399.24M |
|
$219.40M |
|
$184.16M |
|
$-35.24M |
|
$158.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
86.30% |
|
-95.67% |
|
-95.67% |
|
-91.58% |
|
-101.31% |
|
-101.60% |
|
$-421.68M |
|
-- |
|
-- |
|
-- |
|
0.37 |
|
1.70 |
|
|
Receiveable Turnover |
4.60 |
79.36 |
|
-222.95% |
|
-1747.19% |
|
-37.86% |
|
-222.95% |
|
$2.76 |
|
$-4.66 |
|
$-4.57 |
|